Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.
Rhabdomyolysis is an uncommon complication associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. We observed six cases of cerivastatin-associated rhabdomyolysis: two patients developed acute renal failure requiring hemodialysis, and one patient died. Four of the patients had impaired renal function, and five were prescribed drugs with the potential to interact with cerivastatin. Also, five of the six patients presented with symptoms of rhabdomyolysis 3-4 weeks after starting cerivastatin therapy.
Lucas
Robert A
RA
Department of Pharmacy, Saint Thomas Hospital, Nashville, Tennessee 37205, USA. rlucas@stthomas.org
Weathersby
B Blake
BB
Rocco
Vito K
VK
Pepper
J Michael
JM
Butler
Kerry L
KL
D058186:Acute Kidney Injury / Q000139:chemically induced; D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D004347:Drug Interactions; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*; D006435:Renal Dialysis; D051437:Renal Insufficiency / Q000150:complications; D012206:Rhabdomyolysis / Q000139:chemically induced*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin; D003402:Creatine Kinase